Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I

Despite the benefits of currently available preventative and therapeutic interventions, atherosclerotic vascular disease continues to be a major cause of morbidity and mortality in much of the Western World. This emphasize,,, the need for additional preventive and therapeutic interventions exploiting new targets to compliment and augment the results of LDL lowering and other current strategies. One such potential target is HDL and its apolipoproteins, A large body of experimental evidence suggests that augmenting the levels and/or function of HDL and its apolipoproteins can have major vascular protective effects ranging from prevention to stabilization and regression, independent of total or non-HDL cholesterol levels. Therefore, we think that the time is ripe for the development and clinical testing of this new frontier in antiatherogenic strategy. In the present article, We will review the structure/function of HDL and explore means of enhancing the levels and/or function of HDL and its apolipoproteins for vascular protection. (Less)

[1]  M. Eriksson,et al.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. , 1999, Circulation.

[2]  T. Langmann,et al.  Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. , 1999, Biochemical and biophysical research communications.

[3]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[4]  A. Lusis,et al.  Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? , 1998, American journal of human genetics.

[5]  N. Miller Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. , 1987, American heart journal.

[6]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[7]  P. Barter,et al.  Molecular mechanisms of reverse cholesterol transport , 1996, Current opinion in lipidology.

[8]  R. F. Hoyt,et al.  High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase , 1997, Nature Medicine.

[9]  J. Berliner,et al.  The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.

[10]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[11]  E. Rubin,et al.  Evidence that apolipoprotein A-IMilano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[13]  Jing Zhao,et al.  Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. , 1993, The Journal of biological chemistry.

[14]  M. Corretti,et al.  Cholesterol, cholesterol lowering, and endothelial function. , 1998, Progress in cardiovascular diseases.

[15]  C. R. Harper,et al.  New perspectives on the management of low levels of high-density lipoprotein cholesterol. , 1999, Archives of internal medicine.

[16]  A. Callow,et al.  Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[17]  C. Bisgaier,et al.  Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. , 1993, The Journal of biological chemistry.

[18]  R. Lawn,et al.  ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. , 2000, Biochemical and biophysical research communications.

[19]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[20]  A. Reunanen,et al.  Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men , 2000, European journal of clinical investigation.

[21]  M. Brown,et al.  Heart Attacks: Gone with the Century? , 1996, Science.

[22]  J. Berliner,et al.  Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist. , 1997, Advances in experimental medicine and biology.

[23]  E. Rubin,et al.  ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. , 1998, Journal of lipid research.

[24]  D. Bonnefont-Rousselot,et al.  High Density Lipoproteins (HDL) and the Oxidative Hypothesis of Atherosclerosis , 1999, Clinical chemistry and laboratory medicine.

[25]  E. Edelman,et al.  Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. , 2000, The Journal of clinical investigation.

[26]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[27]  N. Grishin,et al.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.

[28]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[29]  J. Crawford,et al.  Of plaques and stones: the SR‐B1 (scavenger receptor class B, type 1) , 1997, Hepatology.

[30]  M. Kashyap Mechanistic studies of high-density lipoproteins. , 1998, The American journal of cardiology.

[31]  M. Aviram Does paraoxonase play a role in susceptibility to cardiovascular disease? , 1999, Molecular medicine today.

[32]  A. Lusis,et al.  Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. , 1997, The Journal of clinical investigation.

[33]  M C Phillips,et al.  Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P. Wilson,et al.  High Density Lipoprotein Cholesterol, Total Cholesterol Screening, and Myocardial Infarction: The Framingham Study , 1988, Arteriosclerosis.

[35]  H. Mabuchi,et al.  Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders (Familial Hypercholesterolemia and CETP Deficiency) and Coronary Heart Disease , 1994 .

[36]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[37]  P. Denéfle,et al.  Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. , 1996, Circulation.

[38]  P. Libby,et al.  Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[39]  A. Lusis,et al.  Lipoprotein oxidation and gene expression in the artery wall. New opportunities for pharmacologic intervention in atherosclerosis. , 1993, Biochemical pharmacology.

[40]  P. Shah,et al.  Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. , 1994, Circulation.

[41]  J. Viikari,et al.  Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. , 1999, Atherosclerosis.

[42]  D. Collen,et al.  Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. , 1997, Circulation.

[43]  R. Mahley,et al.  DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY , 1980 .

[44]  A. Wierzbicki,et al.  HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. , 2000, Current Medical Research and Opinion.

[45]  P. Shah,et al.  Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. , 1992, Circulation.

[46]  J. Berliner,et al.  Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and In vivo inhibition by WEB 2086. , 1999, Circulation research.

[47]  J. Mehta,et al.  Inhibition of arterial thrombus formation by ApoA1 Milano. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[48]  C. Fielding,et al.  Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. McQueen,et al.  Reverse cholesterol transport--a review of the process and its clinical implications. , 1997, Clinical biochemistry.

[50]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[51]  D. Rader,et al.  Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. , 1997, Journal of lipid research.

[52]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[53]  A. Tall,et al.  1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[54]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[55]  A. Hamsten,et al.  Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). , 1997, The American journal of cardiology.

[56]  P. Denéfle,et al.  Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Franceschini,et al.  Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. , 1995, Circulation research.

[58]  E. Rubin,et al.  Cholesteryl Ester Transfer Protein and Atherogenesis , 1997, Annals of the New York Academy of Sciences.

[59]  R. Hovorka,et al.  Effects of intravenous infusion of lipid-free apo A-I in humans. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[60]  R. Stoney,et al.  Relation of Plasma Lipid and Apoprotein Levels to Progressive Intimal Hyperplasia After Arterial Endarterectomy , 1992, Circulation.

[61]  A. Tall,et al.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.

[62]  T. Langmann,et al.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.

[63]  O. Wiklund,et al.  Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. , 1991, European heart journal.

[64]  D. Thelle,et al.  THE TROMSØHEART-STUDY HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE: A PROSPECTIVE CASE-CONTROL STUDY , 1977, The Lancet.

[65]  B. Staels,et al.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.

[66]  G. Franceschini,et al.  Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[67]  A. Tall,et al.  Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. , 1998, Annual review of nutrition.

[68]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[69]  M. Navab,et al.  Monocyte adhesion and transmigration in atherosclerosis. , 1994, Coronary artery disease.

[70]  M. Kashyap Basic considerations in the reversal of atherosclerosis: significance of high-density lipoprotein in stimulating reverse cholesterol transport. , 1989, The American journal of cardiology.

[71]  E. Rubin,et al.  Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. , 1994, Journal of lipid research.

[72]  D. Shih,et al.  Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. , 1996, The Journal of clinical investigation.

[73]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[74]  A. Lusis,et al.  An Absorbing Study of Cholesterol , 2000, Science.

[75]  R. Mahley,et al.  A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. , 1980, The Journal of clinical investigation.

[76]  J. Crouse,et al.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. , 1999, The American journal of cardiology.

[77]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  W. Kannel,et al.  Lipoproteins, cardiovascular disease, and death. The Framingham study. , 1981, Archives of internal medicine.

[79]  A. von Eckardstein,et al.  Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. , 1998, Atherosclerosis.

[80]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[81]  P. Lerch,et al.  Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. , 1999, Arteriosclerosis, Thrombosis and Vascular Biology.

[82]  J. S. Owen,et al.  Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. , 1997, Atherosclerosis.

[83]  P. Shah Plaque disruption and thrombosis: potential role of inflammation and infection. , 1999, Cardiology in review.

[84]  R. Hegele Paraoxonase genes and disease. , 1999, Annals of medicine.

[85]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[86]  A. Lacko,et al.  Physiologic role and clinical significance of reverse cholesterol transport. , 1992, The Journal of the American Osteopathic Association.

[87]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[88]  J. S. Owen,et al.  Role of ABC1 gene in cholesterol efflux and atheroprotection , 1999, The Lancet.

[89]  R. Pasternak,et al.  Effects of serum lipid levels on restenosis after coronary angioplasty. , 1991, The American journal of cardiology.

[90]  V. Fuster,et al.  High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[91]  José A Fernández,et al.  High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.

[92]  J. Gwynne High-density lipoprotein cholesterol levels as a marker of reverse cholesterol transport. , 1989, The American journal of cardiology.

[93]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[94]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[95]  A. Vaughan,et al.  ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. , 2000, Current opinion in lipidology.

[96]  J. Fruchart,et al.  Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. , 1994, Atherosclerosis.

[97]  E. Rubin,et al.  Protein composition determines the anti-atherogenic properties of HDL in transgenic mice , 1993, Nature.

[98]  O. Stein,et al.  Atheroprotective mechanisms of HDL. , 1999, Atherosclerosis.

[99]  A. Vaughan,et al.  The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.

[100]  A. Mendez,et al.  Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. , 1994, The Journal of clinical investigation.

[101]  D. Rader,et al.  Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. , 1999, Circulation.

[102]  G. Fonarow,et al.  formation of , 2022 .

[103]  J P Matts,et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.

[104]  P. Edwards,et al.  Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[105]  S. Harvey,et al.  Structure and function of apolipoprotein A-I and high-density lipoprotein , 2000, Current opinion in lipidology.

[106]  J. Piette,et al.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.

[107]  G. Anantharamaiah,et al.  Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic alpha-helixes. , 1998, Biochemistry.

[108]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[109]  C. Wilhelmsson,et al.  Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors. Apolipoprotein A-I levels in male survivors of myocardial infarction. , 1980, Atherosclerosis.

[110]  Berger Gm High-density lipoproteins, reverse cholesterol transport and atherosclerosis--recent developments. , 1984 .

[111]  P. Moulin,et al.  Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. , 1999, Journal of lipid research.

[112]  Y. Saito Is cholesteryl ester transfer protein (CETP) deficiency atherogenic in familial hypercholesterolemia. , 1998, Internal medicine.

[113]  S. Kaul,et al.  Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. , 1999, The American journal of cardiology.

[114]  J. Slotte HDL receptors and cholesterol efflux from parenchymal cells. , 1990, European heart journal.

[115]  S. Kaul,et al.  Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. , 1998, Circulation.

[116]  D. Spady Reverse cholesterol transport and atherosclerosis regression. , 1999, Circulation.

[117]  M. Mackness,et al.  Low serum paraoxonase: a risk factor for atherosclerotic disease? , 1999, Chemico-biological interactions.

[118]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[119]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[120]  A. Czinner,et al.  Lipoprotein (a) concentrations as risk indicators for atherosclerosis. , 1991, Archives of disease in childhood.

[121]  T. Forte,et al.  The role of apolipoprotein A‐l-containing lipoproteins in atherosclerosis , 1994, Current opinion in lipidology.

[122]  A. Chapelle,et al.  The intrinsic factor–vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein , 1999, Nature Medicine.

[123]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[124]  T. Hayek,et al.  HDL Apolipoprotein A-I Attenuates Oxidative Modification of Low Density Lipoprotein: Studies in Transgenic Mice , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[125]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[126]  J. Auwerx,et al.  Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[127]  P. Shah,et al.  Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. , 1999, Biochemical and biophysical research communications.

[128]  J. Genest,et al.  High density lipoproteins in health and in disease. , 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[129]  P. Kwiterovich The antiatherogenic role of high-density lipoprotein cholesterol. , 1998, The American journal of cardiology.

[130]  S. Hohnloser,et al.  Elevated High-Density Lipoprotein Levels Ameliorate Abnormal Vasoconstriction in Early Atherosclerosis , 2005 .

[131]  R. Vogel Coronary risk factors, endothelial function, and atherosclerosis: A review , 1997, Clinical cardiology.

[132]  C. Sensen,et al.  Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux , 1999, The Lancet.

[133]  A. J. Lusis,et al.  Pathogenesis of Atherosclerosis , 1964, The American journal of cardiology.

[134]  G. Franceschini,et al.  Reverse cholesterol transport: physiology and pharmacology. , 1991, Atherosclerosis.

[135]  V. Fuster,et al.  Role of high density lipoproteins in the regression of atherosclerosis. , 1992, Circulation.

[136]  A. Sharrett,et al.  Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[137]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[138]  A. Zeiher Endothelial modulation of coronary vasomotor tone in humans. Effects of atherosclerosis and risk factors for coronary artery disease. , 1994, Arzneimittel-Forschung.

[139]  P. Durrington,et al.  Human serum paraoxonase. , 1998, General pharmacology.

[140]  S B Hulley,et al.  Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. , 1986, American heart journal.

[141]  P. Denéfle,et al.  Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. , 1999, Circulation.

[142]  S. Yamashita,et al.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[143]  G. Franceschini,et al.  Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[144]  J. Westman,et al.  Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[145]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[146]  K. Hirata,et al.  High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. , 1993, Circulation research.

[147]  M. Connelly,et al.  Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. , 1999, Journal of lipid research.

[148]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[149]  J. Qiao,et al.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. , 1997, The Journal of clinical investigation.

[150]  D. Rader,et al.  Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[151]  G. Fonarow,et al.  Paraoxonase and coronary heart disease. , 2002, Current opinion in lipidology.

[152]  G. Miller High density lipoproteins and atherosclerosis. , 1980, Annual review of medicine.

[153]  A. M. Lefer,et al.  Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[154]  A. Tall,et al.  Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation. Studies in CETP transgenic mice and human genetic CETP deficiency. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[155]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[156]  P. Durrington,et al.  Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[157]  K. Williams,et al.  The response-to-retention hypothesis of atherogenesis reinforced. , 1998, Current opinion in lipidology.

[158]  P. Durrington,et al.  Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification , 1998, FEBS letters.

[159]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[160]  E. Rubin,et al.  HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[161]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[162]  P. Luoma Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. , 1997, Pharmacology & toxicology.

[163]  R. Hegele,et al.  Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.

[164]  D. Rader Gene therapy for atherosclerosis , 1997, International journal of clinical & laboratory research.

[165]  P. Roheim Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport. , 1986, The American journal of cardiology.

[166]  D. Mangelsdorf,et al.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.

[167]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[168]  P. Barter INHIBITION OF ENDOTHELIAL CELL ADHESION MOLECULE EXPRESSION BY HIGH DENSITY LIPOPROTEINS , 1997, Clinical and experimental pharmacology & physiology.

[169]  J. Fruchart,et al.  Apolipoprotein A-I containing lipoproteins in coronary artery disease. , 1987, Atherosclerosis.

[170]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[171]  M C Phillips,et al.  Cell cholesterol efflux: integration of old and new observations provides new insights. , 1999, Journal of lipid research.

[172]  C. Abbott,et al.  Is paraoxonase related to atherosclerosis. , 1993, Chemico-biological interactions.

[173]  The genetic mapping and gene structure of mouse paraoxonase/arylesterase. , 1995, Genomics.

[174]  P. Durrington,et al.  Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation , 1999, The Lancet.

[175]  P. Barter CETP and atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[176]  I. Feuerstein,et al.  Very low high-density lipoproteins without coronary atherosclerosis , 1993, The Lancet.

[177]  S. Kaul,et al.  High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.

[178]  P. Edwards,et al.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.

[179]  K. Saku,et al.  Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. , 1985, Thrombosis research.

[180]  J. Qiao,et al.  Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. , 1993, Science.

[181]  E. Rubin,et al.  Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. , 1997, Biochemistry.

[182]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[183]  S. Horiuchi,et al.  Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[184]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[185]  Seth M. Klein,et al.  Comparison of Class B Scavenger Receptors, CD36 and Scavenger Receptor BI (SR-BI), Shows That Both Receptors Mediate High Density Lipoprotein-Cholesteryl Ester Selective Uptake but SR-BI Exhibits a Unique Enhancement of Cholesteryl Ester Uptake* , 1999, The Journal of Biological Chemistry.

[186]  J. Gamble,et al.  High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase Signaling Pathway , 1999, The Journal of Biological Chemistry.

[187]  J. Huttunen,et al.  The Helsinki Heart Study: central findings and clinical implications. , 1991, Annals of medicine.

[188]  T. Rea,et al.  Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[189]  S. Reddy,et al.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.